bevacizumab,paclitaxel,carboplatin,durvalumab,olaparib
astrazeneca,roche,merck
['ovarian', 'bevacizumab', 'duo-o', 'olaparib', 'durva']
#duo-o study presented at #asco23 proves that adding #durvalumab plus #olaparib &amp; #bevacizumab to advanced-stage #ovariancancer therapy leads to improved pfs. our update from asco 2023 will cover key points! stay tuned. #meded #oncology 
COR2ED bringing you Independent Medical Education developed 
by OBSTETRICS & GYNECOLOGY CONNECT, international experts in obstetrics and gynecology